Bifunctional sulfur-rich macrocyclic chelators and their immunoconjugates for the targeted delivery of theranostic mercury-197
Novel sulfur-rich macrocyclic chelators enable the first targeted delivery of theranostic mercury-197 via antibody immunoconjugates.
Authors
- Valery Radchenko (ORCID: https://orcid.org/0000-0002-4742-6565)
- Conrad Chen
- Caterina F. Ramogida (ORCID: https://orcid.org/0000-0003-4815-2647)
- Parmissa Randhawa (ORCID: https://orcid.org/0000-0002-7280-5524)
- Patrick Davey (ORCID: https://orcid.org/0000-0001-8822-2246)
- A. P. Chu (ORCID: https://orcid.org/0000-0002-0626-5099)
- Raymond M. Reilly (ORCID: https://orcid.org/0000-0003-1038-7993)
- Cristina Rodríguez‐Rodríguez (ORCID: https://orcid.org/0000-0002-3313-4422)
- Helen Merkens (ORCID: https://orcid.org/0000-0003-1958-0167)
- Misaki Kondo
- Zhongli Cai (ORCID: https://orcid.org/0000-0002-8937-4943)
- Shaohuang Chen (ORCID: https://orcid.org/0000-0002-0112-7949)
- Yumeela Ganga-Sah
- Neil Weatherall
Institutions
- BC Cancer Agency (CA)
- TRIUMF (CA)
- University of British Columbia (CA)
- Simon Fraser University (CA)
- University of Toronto (CA)
Publication Details
- Journal
- RSC Pharmaceutics
- Published
- 2025-10-08
- DOI
- https://doi.org/10.1039/d5pm00222b
- Primary Topic
- Synthesis and Characterization of Heterocyclic Compounds
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- TRIUMF
- Canadian Institutes of Health Research
- Natural Sciences and Engineering Research Council of Canada